Event 21 Sep. 2022
Kalidou Gadio Speaks at AIEN 2022 International Energy Summit
News 09 Sep. 2022
France’s Cour de Cassation Confirms Set Aside of EUR 452 Million Award Previously Issued Against Libya
Client Alert 20 Sep. 2022
Unexpected Events from Covid to Supply Chain Disruption: Implications for US Contract, Securities and Antitrust Law
Client Alert 29 Jun. 2022
Discovery, Jurisdiction and Service: Changes in U.S. Law and Implications for Japanese Companies
Article 21 Sep. 2022
E-Commerce Laws in Europe Shape the Future of Fashion
News 23 Sep. 2022
Curtis Recognized by Latin Lawyer 250 (2023)
Event 22 Sep. 2022
Dori Yoldi Speaks to AbogadasMX on Practicing Law Abroad
News 16 Aug. 2022
Curtis Delivers More Firsts for the Government of Oman in its Defense Against U.S. Trade Measures
Event 14 Jun. 2022
Antonia Birt to Speak on Importance of Going Paperless in Arbitration Proceedings at Upcoming Webinar
News 21 Sep. 2022
U.S. Department of State Presents Fulbright Specialist Award to Charles Howland for Project in Uzbekistan
Event 20 Sep. 2022
Susan Maples and Andrew Larkin Speak at the Biennial Conference of ASIL’s International Economic Law Interest Group
Client Alert 30 Aug. 2022
The EU Adopts the “Maintenance and Alignment” Sanctions Package
Client Alert 20 Jul. 2022
The EU Undertakes Fundamental Reform of the Legal Basis for Sanctions Enforcement
Client Alert 24 Jun. 2021
Update on Virtual Notarization (Executive Order 202.7) During the COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021) — U.S. Insight
Update on Virtual Witnessing (New York Executive Order 202.14) During The COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021) — U.S. Insight
Companies operating in the pharmaceutical and related sectors such as healthcare must grapple with cutting-edge scientific development as well as shifting regulatory regimes, which complicate corporate mergers and acquisitions, managing intellectual property portfolios and patents, and litigating disputes. The ethical dimension makes it imperative to have the right legal advice.
Curtis provides a wide range of legal services to clients in the pharmaceutical sector. Our pharmaceutical attorneys advise manufacturers, funds and institutions on transactions and disputes involving branded and generic pharmaceuticals, biotechnology equipment, clinical systems, nanotechnology, medical software and prescription drugs, drug delivery and drug packaging.
We have advised on a diverse range of mergers and acquisitions and other transactions.
The wider Curtis team includes experts in the field of healthcare compliance, as well as former medical doctors and lawyers with experience in pharmaceutical patent and regulatory (Hatch-Waxman) litigation in the U.S.
This has enabled Curtis to develop a range of experience in the pharmaceutical sector, ranging from healthcare issues to compliance and specialist intellectual property. Our healthcare attorneys have also advised on the development and financing of healthcare infrastructure projects such as hospitals in many countries, by way of PPI as well as traditional project finance and Islamic finance.
Intellectual Property Litigation
Commercial Disputes - Litigation
Legal 500 USA, 2019
Legal 500: USA M&A(Middle-Market) 2017
Legal 500 USA 2019